Serum HER-2 Extracellular Domain (ECD) before the First Metastasis in 128 Breast Cancer Patients
Marie-Pichon, F.; Hacene, K.; Guepratte, S.; Neumann, R.
Clinical Laboratory 50(3-4): 163-170
2004
ISSN/ISBN: 1433-6510 PMID: 15074470 Document Number: 9879
We studied the serum HER-2 extracellular domain (sHER-2) before the first metastases in 128/701 breast cancer patients diagnosed and followed-up in our institution who developed metastases as the first relapse. sHER-2 was measured by an enzyme-linked immunosorbent assay and CA 15.3 by an immunoradiometric assay. Non-parametric statistics were used. sHER-2 and CA 15.3 before and after primary treatment were measured in a previous part of the study. Before first metastases, 45% of the samples were over 12 μg/l of sHER-2 (cut-off) and were significantly related to sHER-2 values before and after primary treatment (P=0.0350 and P <0.0001 respectively). Concordance with CA 15.3 was 56.25 % (weak correlation, rho=0.263). sHER-2 levels differed according to the sites of the metastases (P=0.0199), the highest levels were found in liver and lung metastases. A median sHER-2 lead time of 254 days was found for 18/28 (64.3 %) patients before first metastasis. Pre-metastatic sHER-2 levels showed strong univariate (Kaplan-Meier method, P=0.0014) and multivariate prognostic values (Cox model, P<0.0001) for survival after first metastasis. In recurrent breast cancer, elevated levels of sHER-2 enabled an early detection of occult metastases and the identification of patients with a high probability of shortened survival.
Document emailed within 1 workday
